Abstracts tagged "chemokines"

Abstract Number: 079 • 2020 Pediatric Rheumatology Symposium
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis ¹, Denise Pires Marafon ², Ivan Caiello ², Manuela Pardeo ², Giulia Marucci ², Emanuela Sacco ², Giusi Prencipe ², Fabrizio De Benedetti ² and Claudia Bracaglia², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and Secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm. Prompt recognition and early treatment are essential…
Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Julian Torres Vazquez¹, Alejandro Corzo Cruz ², David Alberto Comoto Santacruz ² and Omar Eloy Muñoz Monroy ¹, ¹Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, ²Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…
Abstract Number: 17 • 2019 ACR/ARP Annual Meeting
Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis
Xuan Wang¹, Mara Lennard Richard ¹, Tomika Caldwell ², Brittany Henry ², Tammy Nowling ², Jim Oates ³, Gary Gilkeson ⁴ and Xian Zhang ¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis is a major cause of death in both animal models and human patients. Expression of Fli-1, a member of the Ets family…
Abstract Number: 21 • 2019 ACR/ARP Annual Meeting
Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody
Tomohiro Yamada¹, Jungo Kakuta ¹, Eri Fusaoka-Nishioka ¹, Jun-ichi Ito ², Nobuyuki Yasuda ³, Tetsu Kawano ³ and Toshio Imai ³, ¹KAN Research Institute Inc., Kobe, Japan, ²EISAI Co. Ltd., Tsukuba, Japan, ³KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (FKN) and its solo receptor CX3CR1 are deeply involved in the pathogenesis of rheumatoid arthritis (RA). FKN is expressed on vascular endothelium, while…
Abstract Number: 532 • 2019 ACR/ARP Annual Meeting
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Hayato Hisaki ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 932 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Kentaro Torii ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 997 • 2019 ACR/ARP Annual Meeting
Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis
Maria de la luz Garcia-Hernandez¹, Javier Rangel-Moreno ², Benjamin Korman ², Ananta Paine ¹, Nelson Huertas ³ and Christopher T. Ritchlin ³, ¹Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ²University of Rochester Medical center, Rochester, NY, ³University of Rochester, Rochester, NY
Background/Purpose: DC-STAMP is a transmembrane protein involved in the fusion of mononuclear osteoclasts and essential for the formation of fully functional multinucleated osteoclasts (OCs). Recently…
Abstract Number: 1047 • 2019 ACR/ARP Annual Meeting
CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage
Vasiliki Kalliopi Bournia¹, Markos Patsouras ², Nikolaos Vlachoyiannis ³, Athanasios Tzioufas ⁴, Petros Sfikakis ⁵ and Panagiotis Vlachoyiannopoulos ⁶, ¹1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece, Athens, ³1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, ⁴Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ⁶University General Hospital of Athens “Laiko”, Athens, Greece
Background/Purpose: Recent findings have implicated CXCL4 in the pathogenesis of systemic sclerosis (SSc), while also indicating a potential role of this chemokine as a biomarker…
Abstract Number: 1764 • 2019 ACR/ARP Annual Meeting
CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion
Sadiq Umar¹, Katrien Raemdonck ¹, Karol Palasiewicz ¹, Michael Volin ², Shiva Arami ¹, Suncica Volkov ¹, Nadera Sweiss ¹, M Amin ³ and Shiva shahrara ¹, ¹University of Illinois at chicago, Chicago, IL, ²Department of Microbiology & Immunology, Midwestern University, Downer Grove, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Background/Purpose: CCL25 and its receptor CCR9 have been detected in the inflamed joint; however their role is undefined in rheumatoid arthritis (RA). Hence studies…
Abstract Number: 2920 • 2018 ACR/ARHP Annual Meeting
Correlations of Type I Interferon Score and Interferon Induced Chemokines CXCL10 and CXCL9 with Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis
Gian Marco Moneta¹, Ivan Caiello¹, Lucilla Rava'², Silvia Rosina³, Luisa Bracci Laudiero^1,4, Angelo Ravelli^3,5, Fabrizio De Benedetti⁶ and Rebecca Nicolai⁷, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Epidemiology Unit, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³University of Genova, Genova, Italy, ⁴Institute of Translational Pharmacology, CNR, Roma, Italy, ⁵Rheumatology, Giannina Gaslini Institute, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁷Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Interferons (IFNs) seem to play an important role in the pathogenesis of juvenile dermatomyositis (JDM). We previously reported that expression of both type I…
Abstract Number: 92 • 2018 ACR/ARHP Annual Meeting
Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
Dayvia Russell¹, Margaret Markiewicz², Xian Zhang² and Jim C. Oates³, ¹Research Service, Ralph H. Johnson VA Medical Center, Charleston, SC, ²Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Medical Service, Ralph H. Johnson VA Medical Center, Charleston, SC
Title: Lupus Nephritis Serum Induces Neutrophil Chemotaxis towards Glomerular Endothelial Cells In Vitro Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease associated with…
Abstract Number: 840 • 2018 ACR/ARHP Annual Meeting
The CCL21/CCR7 Axis Drives Vascular, Inflammatory and Destructive Remodeling in Rheumatoid Arthritis
Katrien Van Raemdonck^1,2, Karol Palasiewicz^1,2, Sadiq Umar^1,2 and Shiva Shahrara², ¹Jesse Brown VA Medical Center, Chicago, IL, ²Medicine, Division of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: The synovial tissue of rheumatoid arthritis (RA) patients exhibits abundant expression of CCL21, produced excessively by RA fibroblasts and macrophages. While CCR7 mediates CCL21-driven…
Abstract Number: 983 • 2018 ACR/ARHP Annual Meeting
A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Anders Mellemkjær³, Morten Aagaard Nielsen⁴, Line Dam Heftdal², Marie Iversen³, Peter Schafer⁵ and Bent Deleuran², ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: Targeting intracellular pathways with oral small molecules is an attractive therapeutic approach for treating immune mediated inflammatory diseases. The mitogen-activated protein kinase (MAPK) pathway…
Abstract Number: 987 • 2018 ACR/ARHP Annual Meeting
CCL11 Is Involved in Cell Migration in Rheumatoid Arthritis
Kuninobu Wakabayashi, Takeo Isozaki, Shinichiro Nishimi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is produced by a variety of cell types. By interacting with C-C chemokine receptor…
Abstract Number: 995 • 2018 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice
Kana Hoshino-Negishi¹, Masayoshi Ohkuro², Tomoya Nakatani¹, Wataru Ikeda¹, Yoshikazu Kuboi¹, Naoto Ishii¹, Nobuyuki Yasuda¹ and Toshio Imai³, ¹KAN Research Institute, Inc., Kobe, Japan, ²Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki, Japan, ³President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…

1
2
3
…
8
Next Page »